Coagulation factor IX plays a central role in hemostasis through interaction with factor VIIIa to form the factor X-activating complex at the site of injury. The absence of factor IX activity results in the bleeding disorder hemophilia B. This absence of activity can arise either from a lack of circulating factor IX protein or from mutations that decrease the activity of factor IX. This review focuses on analyzing the structure of factor IX with respect to molecular mechanisms that are at the basis of factor IX function. Proteolytic activation of factor IX to activated factor IX(a) and subsequent structural rearrangements are insufficient to generate fully active factor IXa. Multiple specific interactions between factor IXa, the cofactor VIIIa, and physiological substrate factor X further alter the factor IXa structure to realize the full enzymatic activity of factor IXa. Factor IXa also interacts with inhibitors, extravascular proteins, and cellular receptors that clear factor IX(a) from circulation. Hemophilia B is treated by replacement of the missing factor IX by plasma-derived protein, a recombinant bioequivalent, or via gene therapy. An understanding of how the function of factor IX is tied to structure is leading to modified forms of factor IX that have increased residence time in circulation, higher functional activity, protection from inhibition, and even activity in the absence of factor VIIIa. These modified forms of factor IX have the potential to significantly improve therapy for patients with hemophilia B.
Skip Nav Destination
Review Article|
July 12, 2024
Blood coagulation factor IX: structural insights impacting hemophilia B therapy
Mettine H.A. Bos,
Mettine H.A. Bos
Leiden University Medical Center, Leiden, Netherlands
Search for other works by this author on:
Rianne Elaine van Diest,
Rianne Elaine van Diest
Division of Thrombosis and Hemostasis, Netherlands
Search for other works by this author on:
Dougald M Monroe
UNC Chapel Hill, Chapel Hil, North Carolina, United States
* Corresponding Author; email: dmonroe@med.unc.edu
Search for other works by this author on:
Blood blood.2023023276.
Article history
Submitted:
April 2, 2024
Revision Received:
June 18, 2024
Accepted:
July 8, 2024
Citation
Mettine H.A. Bos, Rianne Elaine van Diest, Dougald M Monroe; Blood coagulation factor IX: structural insights impacting hemophilia B therapy. Blood 2024; blood.2023023276. doi: https://doi.org/10.1182/blood.2023023276
Download citation file:
My Account
Sign InAdvertisement intended for health care professionals
Cited By
Advertisement intended for health care professionals
This feature is available to Subscribers Only
Sign In or Create an Account Close Modal